title: Antiangiogenic effect of methotrexate and PUVA on psoriasis.
abstract: Vascular endothelial growth factor (VEGF) is important factor for angiogenesis in psoriasis. Methotrexate and psoralen and ultraviolet light A (PUVA) mainly target the T cell-mediated immunopathology of psoriasis. Our work aimed at estimating VEGF mRNA in psoriatic patients and investigating whether the standard therapeutic modalities (methotrexate and PUVA) exert their antiangiogenic activity through altering VEGF levels. Twenty-four chronic plaque psoriasis patients were enrolled. Patients were divided into two groups (12 patients each); group A received intramuscular methotrexate and group B was treated by PUVA three times/week in a PUVA 1000 cabin for 10 weeks each. Twelve healthy volunteers served as controls. A skin biopsy was taken from lesional skin before and after treatment for RT-PCR detection of VEGF mRNA. Capillary perfusion scanning using LASER Doppler perfusion imaging was performed on the same psoriatic plaque before and after treatment and was also done for the controls. Following both methotrexate and PUVA, a significant reduction in the amount of VEGF mRNA (P < 0.001 and P = 0.002, respectively) and capillary perfusion (P = 0.002) occurred. These reductions were significantly higher in the methotrexate group (P < 0.001 and  P = 0.001, respectively) than in the PUVA group. The percentage of clinical improvement in the examined psoriatic plaque was significantly positively correlated with the percentage of reduction in the amount of VEGF mRNA (r = 0.850, P < 0.001) and the percentage of reduction in the capillary perfusion (r = 0.684, P < 0.001). Both modalities may exert an antiangiogenic effect. Methotrexate appears to have possibly a more potent antiangiogenic effect than PUVA.
authors.affiliation: Departments of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Cairo University, Cairo, Egypt, olfatshaker@yahoo.com.
authors.forename: Olfat G
authors.initials: OG
authors.lastname: Shaker
authors.forename: Mongy
authors.initials: M
authors.lastname: Khairallah
authors.forename: Hoda M
authors.initials: HM
authors.lastname: Rasheed
authors.forename: Mona R
authors.initials: MR
authors.lastname: Abdel-Halim
authors.forename: Ola M
authors.initials: OM
authors.lastname: Abuzeid
authors.forename: Amira M
authors.initials: AM
authors.lastname: El Tawdi
authors.forename: Heba H
authors.initials: HH
authors.lastname: El Hadidi
authors.forename: Ali
authors.initials: A
authors.lastname: Ashmaui
mesh_terms: D000293:Adolescent; D000328:Adult; D020533:Angiogenesis Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D001775:Blood Circulation / Q000187:drug effects / Q000528:radiation effects; D002196:Capillaries / Q000187:drug effects / Q000503:physiopathology / Q000528:radiation effects; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000494:pharmacology* / Q000627:therapeutic use; D008875:Middle Aged; D011701:PUVA Therapy; D011565:Psoriasis / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D008727:Methotrexate